Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01964859 · ClinicalTrials.gov registry record · Phase 2

Feasibility Study for Fibroblast Autologous Skin Grafts

A Phase 2 study of Wounds and Injuries, sponsored by Johns Hopkins University.

Recruiting
Registry status
Phase 2
Development phase
80
Enrollment target
1
Study location

NCT01964859 is a Phase 2 study of Wounds and Injuries that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 80 participants, below the 501-participant average among 27 other Wounds and Injuries trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01964859, a Phase 2 study of Wounds and Injuries, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
Phase 2
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

This research is being done to determine if investigators can change skin from one type to another. Specifically, investigators are interested in making normal skin into the thicker skin found on our palms and soles.

Conditions Studied

Interventions

  • BIOLOGICAL autologous skin fibroblasts
  • BIOLOGICAL Filler Product

Study Locations (1)

Maryland

  • Johns Hopkins School of Medicine, Dermatology Department - Baltimore

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2015-01-07
Est. Completion 2028-11-01
Phase Phase 2

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT01964859

The ClinicalTrials.gov registry entry for NCT01964859 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 501-participant average among 27 other Wounds and Injuries trials with a reported enrollment target (84% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Wounds and Injuries appearing as the primary indexed condition, and to 2 interventions - of which autologous skin fibroblasts is the first listed.

NCT01964859 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT01964859 about?

NCT01964859 is a clinical study titled "Feasibility Study for Fibroblast Autologous Skin Grafts". This research is being done to determine if investigators can change skin from one type to another. Specifically, investigators are interested in making normal skin into the thicker skin found on our palms and soles.

What is the current status of trial NCT01964859?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2015-01-07. Estimated completion is 2028-11-01.

What conditions does trial NCT01964859 study?

This clinical trial studies the following conditions: Wounds and Injuries.

What interventions are being tested in trial NCT01964859?

The interventions under investigation include: autologous skin fibroblasts (BIOLOGICAL), Filler Product (BIOLOGICAL).

Who is sponsoring clinical trial NCT01964859?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01964859 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Wounds and Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.